Immunogenicity and safety of Pentaxim [Hib-DTaP-poliovirus vaccine] as 3 doses primary vaccination followed by a booster dose at 18 months.

Trial Profile

Immunogenicity and safety of Pentaxim [Hib-DTaP-poliovirus vaccine] as 3 doses primary vaccination followed by a booster dose at 18 months.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2013

At a glance

  • Drugs Hib-DTaP-poliovirus vaccine (Primary) ; DTaP vaccine; Hib vaccine conjugate; Poliovirus vaccine inactivated
  • Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 16 Feb 2010 Actual number of patients added to 792 as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Actual end date added to 1 Jun 2009 as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top